Zobrazeno 1 - 10
of 34
pro vyhledávání: '"E. V. Kataeva"'
Autor:
S. G. Zakharov, T. A. Mitina, A. V. Zakharova, O. P. Madzyara, I. N. Kontievskii, R. V. Vardanyan, E. V. Kataeva, Yu. B. Chernykh, L. L. Vysotskaya, L. V. Ivanitskiy, Yu. Yu. Chuksina, O. R. Zhuravlev, N. V. Gorgun, Z. M. Kharasova, E. V. Trifonova, K. A. Belousov, Z. R. Tekeeva
Publikováno v:
Онкогематология, Vol 19, Iss 2, Pp 109-117 (2024)
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction and decreased platelet production. The formation of antibodies to platelet and megakaryocyte glycoproteins plays a major role in the pathophysiolog
Externí odkaz:
https://doaj.org/article/30d95f9a80694e7ca526cd07cc2bf0e3
Autor:
S. G. Zakharov, T. A. Mitina, A. V. Zakharova, R. V. Vardanyan, E. V. Kataeva, Yu. B. Chernykh, L. L. Vysotskaya, L. V. Ivanitskiy, I. N. Kontievskiy, O. P. Madzyara, O. R. Zhuravlev, N. V. Gorgun, Z. M. Kharasova
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 233-243 (2023)
Glucocorticosteroids (GCS) are the first-line treatment for idiopathic thrombocytopenic purpura (ITP). Despite their high efficacy in patients with newly diagnosed ITP, an adequate level of platelets remains after GCS withdrawal in only less than 20
Externí odkaz:
https://doaj.org/article/d89a53bfbf664be781bf796b9232e6fd
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 36-38 (2022)
Clinical efficiency of Dacogen (inhibitor of DNA hypermethylation) in 16 patients with MDS is presented. Bone marrow cytogenetic studies were performed in 6 patients; the detected chromosome aberrations included 5q deletion in 1 patient, X monosomy i
Externí odkaz:
https://doaj.org/article/97419dbb66be459c8485286dab601154
Autor:
K. A. Belousov, T. A. Mitina, Yu. Yu. Chuksina, A. K. Golenkov, E. V. Kataeva, E. V. Trifonova, Yu. B. Chernykh, L. L. Vysotskaya, S. G. Zakharov, E. F. Klinushkina, A. N. Mitin
Publikováno v:
Онкогематология, Vol 14, Iss 1, Pp 14-19 (2019)
Objective: to study the efficacy and safety of the antitumor RVP program (lenalidomide, bortezomib, prednisone) as a first-line therapy in patients with multiple myeloma (MM). Materials and methods. A prospective study involved 39 patients with MM (1
Externí odkaz:
https://doaj.org/article/9d44a6473ca940b5939c7131d1ff3f5b
Autor:
S. G. Zakharov, A. K. Golenkov, V. A. Misyurin, E. V. Kataeva, M. A. Baryshnikova, Yu. Yu. Chuksina, T. A. Mitina, E. V. Trifonova, L. L. Vysotskaya, Yu. B. Chernykh, E. F. Klinushkina, K. A. Belousov, Yu. P. Finashutina, A. V. Misyurin
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 46, Iss 8, Pp 734-741 (2018)
Background: We have previously shown that the FAS, TNFR2, TRAIL, DR3, DR4/5 gene expression in patients with newly diagnosed chronic lymphoblastic leukemia (CLL) correlates with clinical manifestations of the disease: they are minimal in patients wit
Externí odkaz:
https://doaj.org/article/5700002fb2d745459e510326b80d8937
Autor:
Yu. B. Chernykh, A. K. Golenkov, S. S. Shushanov, T. A. Kravtsova, E. Yu. Rybalkina, A. F. Karamysheva, T. A. Mitina, E. V. Trifonova, E. V. Kataeva, L. L. Vysotskaya, A. A. Stavrovskaya
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 44, Iss 5, Pp 624-630 (2017)
Background: Implementation of a proteasome inhibitor bortezomib into treatment of multiple myeloma has helped to improve survival of patients with this malignancy that is characterized by continuous relapsing course as a clinical manifestation of mul
Externí odkaz:
https://doaj.org/article/94caa4122f9e4aa3848952bfd3104a3a
Autor:
L. L. Vysotskaya, A. K. Golenkov, E. V. Trifonova, T. A. Mitina, E. V. Kataeva, Yu. B. Chernykh
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 0, Iss 41, Pp 60-65 (2016)
Aim: To assess long-term efficacy of firstand second-line tyrosine kinase inhibitors in non-selected patients with chronic myeloid leukemia in a real-life clinical setting.Materials and methods: The assessment is based on long-term results of a prosp
Externí odkaz:
https://doaj.org/article/2bd96839a42b4e6b8f82cf3137b88b80
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 0, Iss 41, Pp 66-71 (2016)
Aim: To assess efficacy of the “7 + 3” regimen in non-selective groups of patients with acute myeloid leukemia (AML).Materials and methods: We retrospectively assessed medical documentations (inand out-patient case histories) of 105 AML patients
Externí odkaz:
https://doaj.org/article/6757b025fdbe4becb5e2c505ff533643
Autor:
T. A. Мitinа, A. K. Golenkov, E. V. Trifonova, E. V. Kataeva, L. L. Vysotskaya, Yu. B. Chernykh, S. G. Zakharov, K. A. Belousov, A. V. Karaulov
Publikováno v:
Онкогематология, Vol 10, Iss 4, Pp 8-14 (2015)
49 patients aged 28 to 81 years old (median age of 55 years old) with relapsed or refractory multiple myeloma (MM) were enrolled in the study. The relapse was diagnosed in 25 (51 %) patients, the refractory disease was determined in 24 (49 %) patient
Externí odkaz:
https://doaj.org/article/3e4430c3202f4d4da6a47c99d238c59d
Autor:
T. D. Lutskaya, A. K. Golenkov, T. A. Mitina, I. V. Buravtsova, G. A. Dudina, L. L. Vysotskaya, E. V. Trifonova, E. V. Kataeva, O. V. Moskalets, V. V. Yazdovskiy
Publikováno v:
Онкогематология, Vol 6, Iss 3, Pp 18-23 (2014)
This study aimed to evaluate treatment results in patients with diffuse large cell lymphoma (DBL CL) received R-CHOP program (as 1 st and2 nd line therapy), including cases with complications. We observed 77 DBLCL patients (50 primary and 27 received
Externí odkaz:
https://doaj.org/article/95c222969ff8490a9bf0f1bd66624731